Exelixis Inc (EXEL) Stock Analysis

Exelixis Inc (EXEL) is a publicly traded company in the HEALTHCARE sector. It trades at $48.54, carries a market capitalization of $12.64B, a price-to-earnings ratio of 16.65. This page summarizes the public market data, fundamentals, and frequently asked questions for EXEL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $48.54
• Market Cap: $12.64B
• P/E Ratio: 16.65
• EPS: $3.02
• 52-Week High: $52.96
• 52-Week Low: $33.76

Market Sentiment

Exelixis Inc currently has a Bullish sentiment score of 0.21.

About Exelixis Inc

Exelixis, Inc. is a prominent biotechnology company based in Alameda, California, specializing in the discovery and development of innovative cancer therapies. With a strong commitment to enhancing patient outcomes, Exelixis has established a robust drug pipeline that reflects its strategic focus on oncology. The company leverages advanced research and development capabilities to deliver transformative treatment solutions, positioning itself as a critical player in the competitive biopharmace...

GNG Research Analysis

GNG Research scores Exelixis Inc (EXEL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for EXEL.

Frequently Asked Questions

Does EXEL pay dividends?

Exelixis Inc (EXEL) does not currently pay a regular dividend.

What is EXEL's P/E ratio?

Exelixis Inc has a price-to-earnings (P/E) ratio of 16.65.

What is EXEL's market cap?

Exelixis Inc (EXEL) has a market capitalization of $12.64B with a current stock price of $48.54.